Zevra Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Zevra Therapeutics

15/05/2023 22:49

* Zevra Therapeutics Inc  ZVRA.OQ  reported a quarterly
adjusted
loss of 34 cents​​ per share for the quarter ended in March. The
mean expectation of four analysts for the quarter was for a loss
of 23 cents per share.
    * Revenue fell 27.4% to $2.88 million from a year ago;
analysts
expected $2.66 million. 
    * Zevra Therapeutics Inc's reported EPS for the quarter was
a loss
of 34 cents​.
    * The mean earnings estimate of analysts had fallen by
about 55%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Zevra Therapeutics Inc shares had fallen by 23.1% this
quarter and lost 7.8% so far this year.
    * The company reported a quarterly loss of $11.77 million.
    * Wall Street's median 12-month price target for Zevra
Therapeutics Inc is $19.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
15 at 09:49 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.23          -0.34          Missed
 Dec. 31 2022      -0.17          -0.26          Missed
 Sep. 30 2022      -0.13          -0.19          Missed
 Jun. 30 2022      -0.12          -0.19          Missed